Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)

April 8, 2026 8:52 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $174.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments